Back to top
more

Senseonics (SENS)

(Delayed Data from AMEX)

$0.40 USD

0.40
5,009,843

-0.03 (-6.92%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $0.40 0.00 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 25% and 4.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?

Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 10.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -35.90% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Computer Programs and Systems (CPSI) Beats Q4 Earnings and Revenue Estimates

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 3.39% and 2.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

Sector ETF report for XHE

Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania

Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Encompass Health (EHC) Plans Hospital to Aid Florida Footprint

Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.

Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform

Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.

Humana (HUM) Brings Home Health Unit of KAH Under CenterWell

Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 25% and 12.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Talkspace, Inc. (TALK) Reports Q2 Loss, Misses Revenue Estimates

Talkspace, Inc. (TALK) delivered earnings and revenue surprises of -15.38% and 4.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Enovis (ENOV) Q2 Earnings Beat Estimates

Enovis (ENOV) delivered earnings and revenue surprises of 20.41% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Beats Q2 Earnings Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Beats Q4 Earnings and Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 133.33% and 0.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Q4 Earnings and Revenues Surpass Estimates

AllScripts (MDRX) delivered earnings and revenue surprises of 154.84% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fullgent Genetics (FLGT) Q4 Earnings and Revenues Surpass Estimates

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?